KraneShares MSCI All China Health Care Index ETF (KURE)
| Assets | $114.58M |
| Expense Ratio | 0.65% |
| PE Ratio | 24.62 |
| Shares Out | 4.80M |
| Dividend (ttm) | $0.01 |
| Dividend Yield | 0.04% |
| Ex-Dividend Date | Dec 28, 2022 |
| Payout Ratio | 1.10% |
| 1-Year Return | -6.65% |
| Volume | 90,077 |
| Open | 23.36 |
| Previous Close | 23.99 |
| Day's Range | 23.05 - 23.36 |
| 52-Week Low | 16.67 |
| 52-Week High | 25.11 |
| Beta | 0.46 |
| Holdings | 86 |
| Inception Date | Feb 1, 2018 |
About KURE
The KraneShares MSCI All China Health Care Index ETF (KURE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market cap-weighted index of large- and mid-cap Chinese stocks in the health care sector. KURE was launched on Feb 1, 2018 and is managed by KraneShares.
Top 10 Holdings
45.09% of assets| Name | Symbol | Weight |
|---|---|---|
| WuXi Biologics (Cayman) Inc | 2269.HK | 8.46% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 300760.SZ | 7.02% |
| BeiGene Ltd Ordinary Shares | 6160.HK | 4.71% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 600276.SS | 4.62% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 4.06% |
| Wuxi AppTec Co Ltd Class A | 603259.SS | 4.05% |
| Aier Eye Hospital Group Co Ltd Class A | 300015.SZ | 4.00% |
| Zhangzhou Pientzehuang Pharmaceutical Co Ltd Class A | 600436.SS | 3.30% |
| Chongqing Zhifei Biological Products Co Ltd Class A | 300122.SZ | 2.60% |
| Sino Biopharmaceutical Ltd | 1177.HK | 2.26% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 28, 2022 | $0.0104 | Dec 30, 2022 |
| Dec 29, 2021 | $4.05345 | Dec 31, 2021 |
| Dec 29, 2021 | $0.00009 | Dec 31, 2021 |
| Dec 29, 2020 | $0.00011 | Dec 31, 2020 |
| Dec 27, 2019 | $0.05733 | Dec 31, 2019 |
| Dec 26, 2018 | $0.03934 | Dec 28, 2018 |
News
China Growth Outlook Could Boost This ETF in 2023
China might not deliver GDP growth on par with the rates seen during the halcyon days of emerging markets investing earlier this century, but the world's second-largest economy could finally be an all...
Foreign Investors Flooding Back into China
Foreign investors are pouring back into China after having been underweight for much of the last year and a half. Over $1.85 billion flowed into Mainland stocks via the Northbound Stock Connect, and i...
Why China's Healthcare Sector Might be the Real Reopening Play
China continues to roll back its COVID-19 zero-tolerance policy, lifting many ongoing quarantines and removing testing requirements that previously prevented the population from moving about cities an...
KURE Could Be Interesting Play Following China Party Congress
China is in the midst of its week-long Party Congress, which was started Sunday with President Xi's two-hour speech, it hasn't been the market-moving event some investors were hoping for, but there ar...
Valuation Opportunities Abound Within China's Healthcare Sector
The health care industry in China is expected to expand rapidly in the coming years with a rapidly aging population, growing infrastructure, and China's growing role in the global health care system t...
KraneShares Debuts Umbrella China ETF
The newest ETF is a fund-of-funds composed of existing China ETFs.
A KURE-All for Bland Healthcare Exposure
In some form or fashion, hundreds of exchange traded funds offer exposure to Chinese equities. As the world's second-largest country has evolved, so have the related ETF offerings.
Healthcare Gains Drive Chinese Stocks Even Higher
Asian markets ended last week up, buoyed in part by a rally in healthcare firms, according to Reuters. The blue-chip CSI300 Index, which tracks the top 300 stocks traded on the Shenzhen Stock Exchange...
Cover All the Hot Bases in Chinese Equity with This Model Portfolio
ETF investors looking for growth and innovation in China, can turn to the KraneShares Krane China Innovation Strategy. The strategy consists of a model portfolio that seeks to provide investors exposu...
5 Top-Performing ETFs of Last Week
Wall Street was downbeat last week on inflationary concerns and some downbeat economic data points.
Is Chinese Healthcare the Miracle KURE for Your Portfolio?
In the United States, healthcare is a dynamic sector home to defensive value stocks, disruptive growth names, and plenty of in-between. China offers a comparable level of healthcare dynamism, which in...
Best Pharmaceutical ETFs for Q2 2021
The best pharmaceutical ETFs for Q2 2021 are KURE, MJJ, and POTX.
China Continues to Be Risky for Investors. What to Expect in 2021.
China risks are on multiple fronts—from the technology rivalry with the U.S. to more regulatory scrutiny inside China of internet giants.
Best Healthcare ETFs for Q1 2021
The best healthcare ETFs for Q1 2021 are ARKG, PTH, and KURE.
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
The Tell: China's bouncing back, but don't bet on other emerging markets to join the ride
China's economy is bouncing back, but other emerging markets aren't likely to enjoy the spoils, says one economist.
Chinese stocks have biggest gains in 3 months
Yahoo Finance's Tom Belger reports on the latest stock news from China and Europe.
Best Healthcare ETFs for Q4 2020
The best healthcare ETFs for Q4 2020 are ARKG, KURE, and PTH.
Best Pharmaceutical ETFs for Q4 2020
The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.
Top 10 Sector ETFs on the Market Today
Sector ETFs and industry funds are different. The 11 sectors addressed in the S&P 500 are as follows (in order of weight in the index): technology, healthcare, consumer discretionary, communication se...
5 Reasons to Bet on China ETFs
The Chinese economy returned to growth in the second quarter of 2020. This along with PBOC's targeted policy easing and China's solid tech industry make China investing winners in the recent trading s...
